Welcome to Medications.com

REFILE-Paradigm Capital lowers Biovail share target - Reuters

Camire also lowered his 2007 revenue outlook by $20 million on worries over lackluster results for Biovail's Ultram ER. Sales of the pain treatment dropped ...

http://www.reuters.com/article/he... | Posted: Fri Nov 09 12:39:14 -0500 2007




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea